Cargando…

Respiratory and sleep disorders in mucopolysaccharidosis

MPS encompasses a group of rare lysosomal storage disorders that are associated with the accumulation of glycosaminoglycans (GAG) in organs and tissues. This accumulation can lead to the progressive development of a variety of clinical manifestations. Ear, nose, throat (ENT) and respiratory problems...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Kenneth I., Fagondes, Simone C., Giugliani, Roberto, Hardy, Karen A., Lee, Kuo Sheng, McArdle, Ciarán, Scarpa, Maurizio, Tobin, Martin J., Ward, Susan A., Rapoport, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590419/ https://www.ncbi.nlm.nih.gov/pubmed/23151682 http://dx.doi.org/10.1007/s10545-012-9555-1

Ejemplares similares

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
por: Braunlin, Elizabeth A., et al.
Publicado: (2011)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012)

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
por: Harmatz, Paul, et al.
Publicado: (2010)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Legal action in sleep medicine: new alternatives need to be sought!
por: Fagondes, Simone Chaves, et al.
Publicado: (2023)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Sleep in the intensive care unit
por: Beltrami, Flávia Gabe, et al.
Publicado: (2015)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
por: Zanetti, Alessandra, et al.
Publicado: (2019)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Recommended respiratory tests are not routinely performed for mucopolysaccharidosis patients
por: Denamur, Sophie, et al.
Publicado: (2021)

Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III
por: Abramova, Anna A., et al.
Publicado: (2021)

Skin-sparing mastectomy with immediate nipple reconstruction during autologous latissimus dorsi breast reconstruction: A review of patient satisfaction
por: Hurley, Ciaran M, et al.
Publicado: (2018)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Formation of Salts and Molecular Ionic Cocrystals of Fluoroquinolones and α,ω-Dicarboxylic Acids
por: O’Malley, Ciaran, et al.
Publicado: (2022)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
por: Shams, Sedigheh, et al.
Publicado: (2017)

Clinical course of sly syndrome (mucopolysaccharidosis type VII)
por: Montaño, Adriana M, et al.
Publicado: (2016)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report
por: Andrade, Isadora, et al.
Publicado: (2022)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Factors Controlling Persistent Needle Crystal Growth: The Importance of Dominant One-Dimensional Secondary Bonding, Stacked Structures, and van der Waals Contact
por: Civati, Francesco, et al.
Publicado: (2021)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Endoscopic and Image Analysis of the Airway in Patients with Mucopolysaccharidosis Type IVA
por: Lee, Yi-Hao, et al.
Publicado: (2023)

Mucopolysaccharidosis-Plus Syndrome
por: Vasilev, Filipp, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sdi9obfogq5u3s2kenul3gndcm